Position in NVS
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$480,503
+$12,172 QoQ
Shares Held
3,066
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#901
of 1,603 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FLC Capital Advisors holds $21,615,806 across 11 Drug Manufacturers - General names. NVS ranks #7 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
86,579 | $11,125,401 | |
| 2 | JNJ |
Johnson & Johnson
|
13,403 | $3,403,959 | |
| 3 | PFE |
Pfizer Inc
|
66,092 | $1,591,495 | |
| 4 | ABBV |
AbbVie Inc.
|
6,063 | $1,525,693 | |
| 5 | LLY |
ELI LILLY & Co
|
1,111 | $1,332,566 | |
| 6 | AMGN |
Amgen Inc
|
2,086 | $755,382 | |
| 7 | NVS |
Novartis AG
This page
|
3,066 | $480,503 | |
| 8 | NVO |
Novo Nordisk A S
|
9,824 | $470,962 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $480,503 | 3,066 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $468,331 | 3,066 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $422,709 | 3,066 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $421,396 | 3,286 | Shares | Sole | 2025-10-17 | |
| 2025-06-30 | $397,638 | 3,286 | Shares | Sole | 2025-07-29 | |
| 2025-03-31 | $288,287 | 2,586 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $251,643 | 2,586 | Shares | Sole | 2025-01-16 | |
| 2024-09-30 | $272,137 | 2,366 | Shares | Sole | 2024-10-16 | |
| 2024-06-30 | $241,238 | 2,266 | Shares | Sole | 2024-07-15 | |
| 2024-03-31 | $219,190 | 2,266 | Shares | Sole | 2024-05-06 | |
| 2023-12-31 | $251,011 | 2,486 | Shares | Sole | 2024-01-18 | |
| No filing history on record for this holder in this stock. | ||||||